This study tests a stronger dose (8mg) of aflibercept in 40 adults with proliferative diabetic retinopathy (PDR) who do not have swelling in the center of the retina. The goal is to see if it can safely improve the severity of the disease and maintain vision over 96 weeks. Partic…
Phase: PHASE4 • Sponsor: Edward Wood, MD • Aim: Disease control
Last updated May 17, 2026 17:20 UTC